Market news

Edgewise Therapeutics' (EWTX) EDG-7500 mechanism reveal accounts for strong clinical showing, lendin

2026-06-17. The following slide deck was published by Edgewise Therapeutics, Inc.

Detailed price information for Csl Ltd (CMXHF) from The Globe and Mail including charting and trades.

Detailed price information for Edgewise Therapeutics Inc (EWTX-Q) from The Globe and Mail including charting and trades.

Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that the CIRRUS-HCM abstract was selected for a late-breaking science presentation at the European Society of Cardiology (ESC) Congress, taking place August 28-31 in Munich, Germany. EDG-7500 is a novel, oral, selective cardiac sarcomere modulator designed to slow early contraction and improve cardiac relaxation in symptomatic HCM while preserving sys

Tenax Therapeutics announced Phase 3 LEVEL trial results for TNX-103, missing primary endpoints while showing subgroup benefits.

Edgewise Therapeutics (EWTX) has an average rating of buy and mean price target of $50.46, according

Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today reported financial results for the second quarter of 2026 and recent business highlights.

How Edgewise Therapeutics Stock Has Been Trading Recently Edgewise Therapeutics (EWTX) has drawn investor attention after a period of mixed short term trading, with the stock down 2.4% over the past day but higher over the past month and past 3 months. Shares last closed at US$38.81, with the company’s total return up about 63% year to date and a much larger gain over the past year. These figures prompt closer scrutiny of what is currently priced into the stock. See our latest analysis for...

Servier, an independent international pharmaceutical group governed by a foundation, today announced that it has completed the acquisition of the muscular dystrophy business of Edgewise Therapeutics Inc. (Nasdaq: EWTX), for up to $2.65 billion, including upfront payment of $1.55 billion as well as up to $1.1 billion in regulatory and commercial milestone payments. This announcement follows regulatory clearance and customary closing conditions.

Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced the successful completion of its previously announced definitive agreement under which Servier, an independent international pharmaceutical group governed by a foundation, acquired sevasemten and Edgewise's muscular dystrophy business for $1.55 billion in upfront cash consideration and up to $1.1 billion in additional milestone payments, for aggregate